Cortigent

Cortigent is a neuroscience-focused medical device company, spun out from Vivani Medical, with a mission to restore lost body functions via targeted brain-surface stimulation. Its core achievement is building upon the legacy of the first FDA-approved retinal prosthesis (Argus II) to develop the next-generation Orion visual cortical prosthesis and a stroke motor recovery system. The company's strategy leverages a proprietary high-channel-count platform to address large neurological indications, though its path is complicated by its subsidiary status and a recently withdrawn planned spin-off from its parent company.

A targeted cortical neurostimulation platform featuring a 60-electrode microelectronic implant placed on the brain's surface, connected to an external data processing unit, designed to deliver precise electrical stimulation to restore neurological function.

Cortigent competes in visual prosthetics against retinal implant companies (Pixium Vision) and emerging cortical BCI players (Neuralink, Science Corp.). In stroke recovery, it faces rehabilitative robotics, non-invasive stimulation, and historical precedent from Northstar Neuroscience. Its differentiators are its 60-electrode cortical array and prior FDA experience from Argus II.